Suppr超能文献

格拉斯哥预后评分可预测接受顺铂治疗的转移性鼻咽癌患者的生存情况不佳。

The Glasgow Prognostic Score predicts poor survival in cisplatin-based treated patients with metastatic nasopharyngeal carcinoma.

作者信息

Chen Cui, Sun Peng, Dai Qiang-sheng, Weng Hui-wen, Li He-ping, Ye Sheng

机构信息

Department of Oncology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.

Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China; Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Guangzhou, China.

出版信息

PLoS One. 2014 Nov 13;9(11):e112581. doi: 10.1371/journal.pone.0112581. eCollection 2014.

Abstract

BACKGROUND

Several inflammation-based prognostic scoring systems, including Glasgow Prognostic Score (GPS), neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) have been reported to predict survival in many malignancies, whereas their role in metastatic nasopharyngeal carcinoma (NPC) remains unclear. The aim of this study is to evaluate the clinical value of these prognostic scoring systems in a cohort of cisplatin-based treated patients with metastatic NPC.

METHODS

Two hundred and eleven patients with histologically proven metastatic NPC treated with first-line cisplatin-based chemotherapy were retrospectively evaluated. Demographics, disease-related characteristics and relevant laboratory data before treatment were recorded. GPS, NLR and PLR were calculated as described previously. Response to first-line therapy and survival data were also collected. Survival was analyzed in Cox regressions and stability of the models was examined by bootstrap resampling. The area under the receiver operating characteristics curve (AUC) was calculated to compare the discriminatory ability of each scoring system.

RESULTS

Among the above three inflammation-based prognostic scoring systems, GPS (P<0.001) and NLR (P = 0.019) were independently associated with overall survival, which showed to be stable in a bootstrap resampling study. The GPS consistently showed a higher AUC value at 6-month (0.805), 12-month (0.705), and 24-month (0.705) in comparison with NLR and PLR. Further analysis of the association of GPS with progression-free survival showed GPS was also associated independently with progression-free survival (P<0.001).

CONCLUSIONS

Our study demonstrated that the GPS may be of prognostic value in metastatic NPC patients treated with cisplatin-based palliative chemotherapy and facilitate individualized treatment. However a prospective study to validate this prognostic model is still needed.

摘要

背景

据报道,包括格拉斯哥预后评分(GPS)、中性粒细胞与淋巴细胞比值(NLR)和血小板与淋巴细胞比值(PLR)在内的几种基于炎症的预后评分系统可预测多种恶性肿瘤的生存率,但其在转移性鼻咽癌(NPC)中的作用仍不清楚。本研究的目的是评估这些预后评分系统在一组接受顺铂治疗的转移性NPC患者中的临床价值。

方法

回顾性评估211例经组织学证实接受一线顺铂化疗的转移性NPC患者。记录治疗前的人口统计学、疾病相关特征和相关实验室数据。按照先前描述的方法计算GPS、NLR和PLR。还收集了一线治疗反应和生存数据。采用Cox回归分析生存情况,并通过自抽样重采样检验模型的稳定性。计算受试者工作特征曲线(AUC)下的面积,以比较各评分系统的鉴别能力。

结果

在上述三种基于炎症的预后评分系统中,GPS(P<0.001)和NLR(P = 0.019)与总生存期独立相关,在自抽样重采样研究中显示稳定。与NLR和PLR相比,GPS在6个月(0.805)、12个月(0.705)和24个月(0.705)时始终显示出更高的AUC值。对GPS与无进展生存期的关联进行进一步分析显示,GPS也与无进展生存期独立相关(P<0.001)。

结论

我们的研究表明,GPS可能对接受顺铂姑息化疗的转移性NPC患者具有预后价值,并有助于个体化治疗。然而,仍需要进行前瞻性研究来验证这一预后模型。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8ff/4230992/aa9b14780529/pone.0112581.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验